Canadian Sec - Delayed Quote CAD

BioNxt Solutions Inc. (BNXT.CN)

0.2600 0.0000 (0.00%)

At close: November 3 at 11:35:37 AM EST

Chart Range Bar

Loading chart for BNXT.CN

Previous Close 0.2600
Open 0.2600
Bid 0.2500 x --
Ask 0.3350 x --
Day's Range 0.2600 - 0.2600
52 Week Range 0.2550 - 0.8400
Volume 4,500
Avg. Volume 28,176
Market Cap (intraday) 35.384M
Beta (5Y Monthly) 1.58
PE Ratio (TTM) --
EPS (TTM) -0.0700
Earnings Date (est.) --
Forward Dividend & Yield -- (0.00%)
Ex-Dividend Date --
1y Target Est --

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation; and BNT24006, an oncology drug targeting chemotherapy platform and anticancer mTOR inhibitor. It also offers diagnostic and biosensor screening tests; transdermal patches and oral dissolvable formulations; and development of psychedelic medicine to treat mental health-related medical conditions, such as depression, anxiety, addiction, and trauma-related stress disorder. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

www.bionxt.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

BNXT.CN

57.38%

S&P/TSX Composite index (^GSPTSE)

11.50%

1-Year Return

BNXT.CN

67.90%

S&P/TSX Composite index (^GSPTSE)

17.42%

3-Year Return

BNXT.CN

26.76%

S&P/TSX Composite index (^GSPTSE)

79.23%

5-Year Return

BNXT.CN

81.29%

S&P/TSX Composite index (^GSPTSE)

67.09%

Earnings Per Share (GAAP)

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q4 FY21

Revenue 123.43k

Earnings -6.64M

Profit Margin -5,378.81%

FY21

-6M

-4M

-2M

-5000.0%

-4000.0%

-3000.0%

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-387.49%
Return on Equity (ttm)

--
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-9.14M
Diluted EPS (ttm)

-0.0700

Balance Sheet and Cash Flow

Total Cash (mrq)

1.2M
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

-2.87M

DTC.CN Defence Therapeutics Inc.

0.3400 +19.30%

FHYD.V First Hydrogen Corp.

0.2950 -1.67%

NRX.V NurExone Biologic Inc.

0.5000 -1.96%

KDA.V KDA Group Inc.

0.0500 -16.67%

INNO.CN InnoCan Pharma Corporation

1.9000 0.00%

U.S. markets closed

BioNxt Solutions Inc. (BNXT.CN)

-10.34%

-31.58%

-48.00%

-57.38%

-67.90%

-81.29%

-69.77%

BioNxt Solutions Inc. Overview Drug Manufacturers - Specialty & Generic / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share (GAAP)

Revenue vs. Earnings

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch